SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

NextDecade Corp. is a development company, which focuses on liquefied natural gas (LNG) export projects and associated pipelines. It develops and manages land-based and floating liquefied natural gas projects in the Gulf Coast with focus on the Rio Grande LNG. The company was founded by Kathleen Eishbrenner in 2010 and is headquartered in Houston, TX.

NextDecade Corporation

NextDecade is currently a focal point for investors as the company makes significant strides in its Rio Grande LNG project, including regulatory progress on expansion trains and major equity investments from institutional partners like Hanwha. While some market participants express caution regarding the project's long-term capital intensity and the timeline to profitability, the community is actively debating the company's potential as a strategic energy infrastructure asset and closely monitoring insider buying activity for signs of confidence.

Intuitive Surgical, Inc. engages in the provision of robotic-assisted surgical solutions and invasive care through a comprehensive ecosystem of products and services. Its products include Da Vinci Surgical and Ion Endoluminal systems. The company was founded by Frederic H. Moll, John Gordon Freund, and Robert G. Younge in November 1995 and is headquartered in Sunnyvale, CA.

Intuitive Surgical Inc

Intuitive Surgical is experiencing significant market interest ahead of its upcoming earnings report, with the community closely watching the da Vinci 5 platform's impact on procedure growth and margin sustainability. Investors are actively debating the stock's valuation and potential upside, with many analyzing the company's competitive moat against tariff pressures and broader sector trends.

United States Commodity Funds LLC - United States Brent Crude Oil Fund

The United States Brent Oil Fund is under intense market scrutiny as investors grapple with escalating geopolitical instability in the Middle East and concerns over global supply chain disruptions. Community discussions are heavily focused on the potential for price volatility linked to supply-demand imbalances, with some traders debating the merits of long positions amid persistent inflationary pressures and broader economic uncertainty.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+, and TMTG News. It operates through the Media and Truth.Fi segments. The Media segment includes products and services such as advertisement through the Truth Social platform. The Truth.Fi segment relates to customized exchange-traded funds or exchange-traded products invested in America First principles, and bitcoin and similar cryptocurrencies or crypto-related securities. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

Trump Media & Technology Group is trending as investors grapple with extreme volatility driven by the administration's military maneuvers in Iran, which have sparked intense debate over potential economic impacts, energy sector instability, and the company's long-term viability. Community discourse is highly polarized, with users clashing over the geopolitical strategy, insider selling, and the stock's significant decline toward all-time lows.

Sable Offshore Corp. engages in offshore oil and gas field operations. It focuses on developing the prolific Santa Ynez Unit in federal waters offshore California. The company was founded by James C. Flores on October 16, 2020 and is headquartered in Houston, TX.

Sable Offshore Corp.

Sable Offshore is trending as investors react to the Trump administration's invocation of the Defense Production Act to potentially override California's environmental regulations and expedite the restart of the company's offshore pipeline operations. The community is heavily focused on the stock's significant short interest and the potential for a massive short squeeze, while traders weigh the tension between federal energy-security directives and ongoing state-level legal hurdles.

Stellantis NV engages in the designing, engineering, manufacturing, distributing, and selling of vehicles and components. It offers its products under the Abarth, Alfa Romeo, Chrysler, Citroën, Dodge, DS Automobiles, Fiat, Jeep, Lancia, Maserati, Opel, Peugeot, Ram Trucks, Vauxhall, Free2move, and Leasys brands. The company was founded on April 1, 2014 and is headquartered in Hoofddorp, the Netherlands.

Stellantis N.V

Stellantis is currently trending due to a major $13 billion investment plan in its U.S. manufacturing operations, which aims to add 5,000 jobs and expand production capacity. Investors are closely scrutinizing this strategic pivot as the company balances this capital-intensive turnaround with ongoing concerns regarding operational execution and recent volume fluctuations.

Meta Platforms, Inc. engages in the development of social media applications. It builds technology that helps people connect and share, find communities, and grow businesses. It operates through the Family of Apps (FoA) and Reality Labs (RL) segments. The FoA segment consists of Facebook, Instagram, Messenger, WhatsApp, and other services. The RL segment includes augmented, mixed and virtual reality related consumer hardware, software, and content. The company was founded by Mark Elliot Zuckerberg, Dustin Moskovitz, Chris R. Hughes, Andrew McCollum, and Eduardo P. Saverin on February 4, 2004, and is headquartered in Menlo Park, CA.

Meta Platforms Inc - Ordinary Shares - Class A

Meta Platforms Inc

Meta Platforms is currently trending as investors debate the impact of reportedly delayed AI model rollouts, with community sentiment sharply divided between those viewing the pullback as a buying opportunity and others concerned about heavy AI infrastructure spending. Traders are closely monitoring the stock's consolidation around key technical support levels while tracking internal cost-saving initiatives and broader market sensitivity to AI-driven capital expenditure.

Immuneering Corp. operates as a clinical-stage oncology company, which engages in developing medicines for cancer patients. Its pipeline of drug candidates focuses on treating aspects of disease that have eluded conventional approaches, including cancer cachexia and metastasis. The company was founded by Robert J. Carpenter and Benjamin J. Zeskind in 2008 and is headquartered in Cambridge, MA.

Immuneering Corp - Ordinary Shares Class A

Immuneering Corp

Immuneering Corp is capturing significant investor attention as the community anticipates critical 12-month overall survival data for its lead oncology candidate, atebimetinib. The stock is currently trending due to its recent addition to the Nasdaq Biotechnology Index and ongoing discussions regarding its competitive positioning as a potential buyout target, with participants actively debating the strength of its survival metrics compared to other industry players.

InMode Ltd. designs, develops, manufactures and markets minimally-invasive aesthetic medical products. It also designs, develops, manufactures and markets non-invasive medical aesthetic products that target a array of procedures including permanent hair reduction, facial skin rejuvenation, wrinkle reduction, cellulite treatment, skin appearance and texture and superficial benign vascular and pigmented lesions. The company was founded by Moshe Mizrahy and Michael Kreindel on January 2, 2008 and is headquartered in Yokneam, Israel.

Inmode Ltd

InMode (INMD) is trending as shareholders react to the company's decision to launch a significant new share repurchase program, aiming to capitalize on what management perceives as an undervalued share price. The community remains divided, with some investors viewing the buyback as a positive signal of stability and value, while others remain skeptical, citing ongoing concerns about management's communication, the impact of macroeconomic headwinds on aesthetic procedure demand, and the company's strategic outlook.

Monero

Monero (XMR) is currently at the center of a polarizing debate within the crypto community, as bullish sentiment regarding its role as a premier privacy-focused, fungible digital currency clashes with ongoing regulatory concerns and broader market skepticism. Investors are actively debating the long-term impact of its delisting from major centralized exchanges, with proponents viewing this as a sign of true decentralization and resilience while critics question its long-term viability compared to mainstream assets like Bitcoin.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

MREO Investors Have Opportunity to Lead Mereo BioPharma Group plc Securities Fraud Lawsuit with the Schall Law Firm

MREO Investors Have Opportunity to Lead Mereo BioPharma Group plc Securities Fraud Lawsuit with the Schall Law Firm MREO Investors Have Opportunity to Lead Mereo BioPharma Group plc Securities Fraud...

Mereo BioPharma Group plc Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - MREO

Mereo BioPharma Group plc Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - MREO Mereo BioPharma Group plc Sued for Securities Law Violations - Contact the DJS...

MREO SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Reminds Mereo (MREO) Investors of Securities Class Action Deadline on April 6, 2026

MREO SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Reminds Mereo (MREO) Investors of Securities Class Action Deadline on April 6, 2026 MREO SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Reminds Mereo...

LEVI & KORSINSKY, LLP: CEO AND CSO NAMED AS CONTROL PERSON DEFENDANTS IN MEREO BIOPHARMA SECURITIES ACTION

LEVI & KORSINSKY, LLP: CEO AND CSO NAMED AS CONTROL PERSON DEFENDANTS IN MEREO BIOPHARMA SECURITIES ACTION LEVI & KORSINSKY, LLP: CEO AND CSO NAMED AS CONTROL PERSON DEFENDANTS IN MEREO BIOPHARMA...

Class Action Filed Against Mereo BioPharma Group plc (MREO) - April 6, 2026 Deadline to Join - Contact The Gross Law Firm

Class Action Filed Against Mereo BioPharma Group plc (MREO) - April 6, 2026 Deadline to Join - Contact The Gross Law Firm Class Action Filed Against Mereo BioPharma Group plc (MREO) - April 6, 2026...

MREO SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Reminds Mereo BioPharma Investors of Securities Class Action Deadline on April 6, 2026

MREO SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Reminds Mereo BioPharma Investors of Securities Class Action Deadline on April 6, 2026 MREO SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP...

MREO Investors Have Opportunity to Lead Mereo BioPharma Group plc Securities Fraud Lawsuit

MREO Investors Have Opportunity to Lead Mereo BioPharma Group plc Securities Fraud Lawsuit MREO Investors Have Opportunity to Lead Mereo BioPharma Group plc Securities Fraud Lawsuit PR Newswire NEW...

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Mereo BioPharma Group plc of Class Action Lawsuit and Upcoming Deadlines - MREO

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Mereo BioPharma Group plc of Class Action Lawsuit and Upcoming Deadlines - MREO INVESTOR ALERT: Pomerantz Law...

LEVI & KORSINSKY, LLP: CHRONOLOGY OF EVENTS IN THE MEREO BIOPHARMA SECURITIES CLASS ACTION

LEVI & KORSINSKY, LLP: CHRONOLOGY OF EVENTS IN THE MEREO BIOPHARMA SECURITIES CLASS ACTION LEVI & KORSINSKY, LLP: CHRONOLOGY OF EVENTS IN THE MEREO BIOPHARMA SECURITIES CLASS ACTION PR Newswire NEW...

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of April 6, 2026 in Mereo Lawsuit - MREO

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of April 6, 2026 in Mereo Lawsuit - MREO The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of April 6, 2026 in...

Mereo BioPharma Group Plc is a biopharmaceutical company, which engages in the development and commercialization of therapeutics that aim to improve outcomes for oncology and rare diseases. Its portfolio include Etigilimab (MPH-313), Alvelestat (MPH-966), Setrusumab (BPS-804), Navicixizumab (OMP-305B83), Acumapimod (BCT-197), and Leflutrozole (BGS-649). The company was founded by Denise Vera Scots-Knight, Charles Edward Sermon, Alastair Graham MacKinnon, and John P. Richard in March 10, 2015 and is headquartered in London, the United Kingdom.

Current Price	$0.386
Prev Close	$0.3869
Open	$0.3849
Dividend Yield	0.00%
50-Day Moving Average	$0.4484
Beta	1.65
Avg. Volume	3.2M
PE Ratio	-1.46

52-Week High	$3.05
52-Week Low	$0.20
Market Capitalization	$61.41M
EPS (Annual)	-$0.2925
Price to Book	1.32
Revenue Per Employee	$0.00

MREO
Mereo Biopharma

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest MREO News

MREOMereo Biopharma